国泰海通证券股份有限公司 关于广东泰恩康医药股份有限公司 开展外汇套期保值业务的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐机构"）作为 广东泰恩康医药股份有限公司（以下简称"泰恩康"、"公司"）首次公开发行 股票并在创业板上市的保荐机构及持续督导机构，根据《证券发行上市保荐业务 管理办法》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有 关规定，对泰恩康拟开展外汇套期保值业务相关事项进行了核查，具体情况如下： 一、投资情况概述 （一）投资目的 公司日常经营中存在跨境交易，发生外币收支业务，为了减小和防范汇率或 利率风险，合理降低财务费用，降低汇率波动对公司及子公司经营的影响，公司 及子公司拟基于实际业务需要，以套期保值为目的，开展外汇衍生品交易业务， 不进行单纯以投机为目的的外汇交易，资金使用安排合理，不影响公司及子公司 主营业务的发展。 （二）交易金额及期限 三、交易风险分析及风控措施 （一）外汇衍生品交易业务的风险分析 预计任一交易日持有的最高合约价值金额不超过 4,000 万元人民币或等值 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-084 广东泰恩康医药股份有限公司 关于公司聘任高级管理人员的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 董事会 2025 年 12 月 26 日 附件 郑锐涵先生简历 郑锐涵，男，出生于 1994 年 8 月，中国国籍，无境外永久居留权，硕士研 究生学历。2020 年 5 月至今任职广东泰恩康科技实业有限公司总经理，现任公 司副总经理。 广东泰恩康医药股份有限公司（以下简称"公司"）于 2025 年 12 月 26 日 召开第五届董事会第十二次会议，审议通过了《关于聘任郑锐涵为公司副总经理 的议案》《关于聘任林姿丽为公司副总经理的议案》。 为适应公司的发展需要，完善公司治理结构，根据《中华人民共和国公司法》 《中华人民共和国证券法》等法律、法规、规范性文件及《公司章程》的有关规 定，经总经理郑汉杰先生提名，董事会提名委员会审议通过，董事会同意聘任郑 锐涵先生为公司副总经理，协助总经理分管全面日常工作；同意聘任林姿丽女士 为公司副总经理，分管总经办、业务部、质管部等部门。郑锐涵先生与林姿丽女 ...

广东泰恩康医药股份有限公司 关于公司开展外汇套期保值业务的可行性分析报告 一、投资情况概述 （一）投资目的 公司日常经营中存在跨境交易，发生外币收支业务，为了减小和防范汇率或 利率风险，合理降低财务费用，降低汇率波动对公司及子公司经营的影响，公司 及子公司拟基于实际业务需要，以套期保值为目的，开展外汇衍生品交易业务， 不进行单纯以投机为目的的外汇交易，资金使用安排合理，不影响公司及子公司 主营业务的发展。 （二）交易金额及期限 预计任一交易日持有的最高合约价值金额不超过 4,000 万元人民币或等值外 币金额，预计动用的交易保证金和权利金上限（包括为交易而提供的担保物价值、 预计占用的金融机构授信额度、为应急措施所预留的保证金等）不超过 1,000 万 元人民币或等值外币金额。本次开展的外汇衍生品交易业务额度期限为自公司董 事会审议通过之日起 12 个月，在授权期限内该额度可循环使用，期限内任一时 点的交易金额（含前述交易的收益进行再交易的相关金额）将不超过已审议额度， 如单笔交易的存续期超过了授权额度期限的有效期，则授权额度期限的有效期自 动顺延至单笔交易终止时止。董事会授权公司董事长在上述额度范围内行使外 ...

Group 1 - The core viewpoint of the news is that Taiankang's stock has shown significant fluctuations, with a year-to-date increase of 88.70% and a recent decline over the past 60 days of 18.68% [1] - As of December 24, Taiankang's stock price was 27.91 yuan per share, with a market capitalization of 11.876 billion yuan [1] - The company has seen a net inflow of main funds amounting to 1.1218 million yuan, with large orders accounting for 14.42% of total buying [1] Group 2 - For the period from January to September 2025, Taiankang reported a revenue of 526 million yuan, a year-on-year decrease of 8.13%, and a net profit attributable to shareholders of 31.4052 million yuan, down 73.00% year-on-year [2] - The number of shareholders increased by 9.32% to 12,000, while the average circulating shares per person decreased by 8.53% to 25,381 shares [2] - Since its A-share listing, Taiankang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3]

Core Insights - Guangdong Taiankang Pharmaceutical Co., Ltd. announced a significant breakthrough with its subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. receiving a drug registration certificate for Finasteride and Tadalafil capsules, branded as Aitinglie, making it the first company in China to obtain approval for this medication [1][2] - The combination drug exhibits unique multi-target therapeutic advantages for treating benign prostatic hyperplasia (BPH), containing 5mg of Finasteride and 5mg of Tadalafil, addressing different pathological mechanisms of BPH [1] Company Developments - The approval of Aitinglie fills a market gap for combination therapies for BPH in China, as the drug was previously developed by the U.S. company VERU and approved by the FDA in December 2021 [2] - Taiankang plans to launch Aitinglie in the first quarter of next year, which is expected to significantly contribute to the company's performance and enhance its product portfolio in the urology and geriatric treatment sectors [2] - The new drug approval strengthens the company's research and industrialization capabilities in chemical pharmaceuticals, injecting new growth momentum and improving its core competitiveness and market influence [2]

Group 1 - Kangnibei Group plans to transfer up to 5,065,900 shares, representing no more than 2% of the total share capital, to its controlling shareholder, Zhejiang Pharmaceutical Group, through a block trade [1] - Guiguan Network elected Dai Qingsong as the chairman of the fifth board of directors, who will also act as the general manager [2] - Huayin Technology's shareholders plan to transfer a total of 10,725,600 shares, accounting for 3.93% of the total share capital [3] Group 2 - Wireless Media's subsidiary won a bid for an AI-enabled media platform project with a contract amount of 4.8895 million yuan [4] - Chaosheng Electronics plans to invest 1.008 billion yuan in a high-performance HDI circuit board expansion and upgrade project, aiming to increase production capacity by 240,000 square meters annually [5] - Yingfeng Co., Ltd. disclosed a plan to raise no more than 522 million yuan through a private placement for various projects [6] Group 3 - Yongtai Technology's executives plan to collectively increase their holdings by no less than 5 million yuan without a price range [7] - Guangdong Construction's subsidiary's wind power project has successfully connected its first unit to the grid, contributing to a total installed capacity of 5,094.52 MW [8] - *ST Jiaotou was selected as the first candidate for a sewage treatment plant project with an estimated contract value of 128 million yuan [9] Group 4 - Sanhua Intelligent Control expects a net profit of 3.874 billion to 4.649 billion yuan for 2025, representing a year-on-year increase of 25% to 50% [10] - Aolian Electronics is planning a change in control, leading to a temporary suspension of its stock [11] - ST Zhengtong will resume trading on December 24 after lifting risk warnings and changing its stock name [12] Group 5 - China Nonferrous Metal Industry's subsidiary acquired a 99.9004% stake in Raura Company for 106 million USD, which includes a zinc polymetallic mine in Peru [13] - Xusheng Group's actual controller will change to the Guangzhou Municipal Government, with stock resuming trading [14] - Hualian Holdings plans to acquire 100% of Argentum Lithium S.A. for approximately 1.75 billion USD [15] Group 6 - Yichang Technology is planning a change in control, leading to a temporary suspension of its stock [16] - Runyang Technology's controlling shareholder intends to transfer 5% of the company's shares at a price of 30.08 yuan per share [17] - Hongqi Chain's shareholder, Yonghui Supermarket, plans to reduce its holdings by up to 3% [18][19] Group 7 - Jiaojian Co., Ltd.'s actual controller is under criminal investigation, but the company's control has not changed [20][29] - Tianji Technology is facing a lawsuit for alleged collusion in bidding [21] - Yuehai Feed's controlling shareholder plans to reduce its holdings by up to 3% [22][23] Group 8 - Bojie Co., Ltd. plans to distribute a cash dividend of 0.94 yuan per 10 shares for the 2025 interim period [24] - Dongjiang Environmental plans to invest up to 12 million yuan in a capital increase for a technology company [25] - Taiankang's product received a drug registration certificate for a combination treatment for benign prostatic hyperplasia [26] Group 9 - Lingyun Optical plans to invest up to 5 million USD in a cornerstone investment for an IPO [27] - Canar Co., Ltd. intends to acquire 70% of Jiangxi Fenglin for 21 million yuan [28] - Enjie Co., Ltd.'s subsidiary received a government subsidy of 20 million yuan, accounting for 3.6% of the latest audited net profit [34] Group 10 - China Nuclear Construction plans to introduce investors for a total capital increase of 5 billion yuan, maintaining control over its subsidiaries [35] - Xinzhu Co., Ltd. signed a framework cooperation agreement for an integrated energy project in Tibet [36] - Beibo Co., Ltd. plans to establish a holding subsidiary focused on high-temperature industrial equipment [37] Group 11 - Emei Mountain A plans to establish a wholly-owned subsidiary for tea industry integration with an investment of 10 million yuan [38] - Tianpu Co., Ltd. confirmed the results of a tender offer, with a total of 201 shares accepted [39] - *ST Dongtong's stock will be delisted, entering a 15-day delisting period [40] Group 12 - Zhuoran Co., Ltd.'s subsidiary signed a significant order worth 4.033 billion yuan for a project, representing 142.09% of the company's expected revenue for 2024 [41]

Core Viewpoint - The company TianKang (301263.SZ) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd. (referred to as "Huabo Kaisheng"), has received a drug registration certificate from the National Medical Products Administration for Finasteride and Tadalafil Capsules, making it the first company in China to obtain this certification [1]. Group 1 - Huabo Kaisheng is the first company in China to receive a drug registration certificate for Finasteride and Tadalafil Capsules [1]. - The drug is a combination formulation consisting of Finasteride, a 5α-reductase inhibitor, and Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, specifically designed to treat symptoms of benign prostatic hyperplasia (BPH) [1]. - The combination of these two components provides a synergistic therapeutic effect, with Finasteride reducing prostate volume and alleviating urinary difficulties, while Tadalafil directly relieves lower urinary tract symptoms associated with BPH [1].

Core Viewpoint - The company TianKang (301263.SZ) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd. (referred to as "Huabo Kaisheng"), has received a drug registration certificate from the National Medical Products Administration for Finasteride and Tadalafil Capsules, making it the first company in China to obtain this certification for this drug combination [1]. Group 1 - Huabo Kaisheng is the first company in China to receive a drug registration certificate for Finasteride and Tadalafil Capsules [1]. - The drug is a combination of Finasteride, a 5α-reductase inhibitor, and Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, specifically designed to treat symptoms of benign prostatic hyperplasia (BPH) [1]. - The combination of these two drugs provides a synergistic therapeutic effect, with Finasteride reducing prostate volume and alleviating urinary difficulties, while Tadalafil directly relieves lower urinary tract symptoms associated with BPH [1]. Group 2 - Tadalafil also has the added benefit of improving erectile function, addressing potential erectile dysfunction side effects that may arise from Finasteride treatment [1].

Core Viewpoint - The company TianKang (301263.SZ) has received a drug registration certificate from the National Medical Products Administration for its compound formulation of Finasteride and Tadalafil capsules, marking a significant milestone as the first company in China to obtain this certification for this specific drug combination [1]. Group 1: Product Details - The Finasteride and Tadalafil capsules are designed to treat symptoms of benign prostatic hyperplasia (BPH), utilizing the synergistic effects of both components [1]. - Finasteride, a 5α-reductase inhibitor, helps reduce prostate volume and alleviate urinary difficulties, while Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, directly addresses lower urinary tract symptoms associated with BPH [1]. - Tadalafil also has the added benefit of improving erectile function, potentially counteracting erectile dysfunction side effects that may arise from Finasteride treatment [1]. Group 2: Market Position - As of now, no other companies in China have received a drug registration certificate for Finasteride and Tadalafil capsules, positioning the company as a pioneer in this market segment [1].

Core Viewpoint - The announcement highlights the approval of a new drug, Finasteride and Tadalafil capsules, by the National Medical Products Administration, indicating a significant development for the company in the pharmaceutical sector [1]. Company Summary - Tiancong (301263) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a drug registration certificate for Finasteride and Tadalafil capsules from the National Medical Products Administration [1]. - The new formulation is a combination of Finasteride and Tadalafil, specifically designed to treat the signs and symptoms of benign prostatic hyperplasia in men [1].